Bradbury Daniel's Form 4/A amendment
AmendedCastle Biosciences Inc (CSTL) · filed Jun 13, 2022
- Accession no.
- 0001447362-22-000111
- Filed
- Jun 13, 2022
- Trade date
- Jan 4, 2022
- Filing delay
- 160 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 6, 2022
This filing lists 3 non-derivative transactions. It carries over 6 transactions from the original filing that it did not restate. Open-market sales total $1.59M. It was filed 160 days after the trade.
This amendment restates part of 0001447362-22-000007 (filed Jan 6, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bradbury DanielCIK 0001236397 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2022 | Common Stock | SSaleDisposed | −7,303 | $43.92F2 | −$320,747.76 | 238,690 | Indirect | |
| Jan 4, 2022 | Common Stock | SSaleDisposed | −4,375 | $43.02F4 | −$188,212.5 | 130,905 | Indirect | |
| Jan 4, 2022 | Common Stock | SSaleDisposed | −4,375 | $43.46F6 | −$190,137.5 | 130,930 | Indirect |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001447362-22-000007 (filed Jan 6, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2022 | Common Stock | SSaleDisposed | −4,618 | $43.50F7 | −$200,883 | 130,687 | Indirect | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −2,763 | $43.21F9 | −$119,389.23 | 236,113 | Indirect | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −4,840 | $43.64F10 | −$211,217.6 | 231,273 | Indirect | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −4,375 | $40.44F11 | −$176,925 | 126,287 | Indirect | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −2,477 | $41.04F12 | −$101,656.08 | 128,210 | Indirect | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −1,898 | $42.09F13 | −$79,886.82 | 126,312 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F7
This transaction was executed in multiple trades at prices ranging from $43.305 to $43.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $42.470 to $43.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $43.470 to $44.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F11
This transaction was executed in multiple trades at prices ranging from $40.280 to $40.670, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F12
This transaction was executed in multiple trades at prices ranging from $40.670 to $41.660, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F13
This transaction was executed in multiple trades at prices ranging from $41.820 to $42.470, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.
- F2
This transaction was executed in multiple trades at prices ranging from $43.750 to $44.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.
- F4
This transaction was executed in multiple trades at prices ranging from $42.695 to $43.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
- F6
This transaction was executed in multiple trades at prices ranging from $43.300 to $43.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F7
Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
Remarks
This amendment is being filed to correct certain clerical errors in lines 1, 3 and 4 of Table I included in the Form 4 originally filed by the Reporting Person on January 6, 2022. This amendment corrects the allocation of shares sold on January 4, 2022, the weighted average sale prices and the range of sale prices for each transaction.